Brand name authorized in: United Kingdom United States
The drug ACTHREL contains one active pharmaceutical ingredient (API):
Corticorelin results in a rapid and sustained increase of plasma ACTH levels and a near parallel increase of plasma cortisol. In addition corticorelin causes a concomitant and prolonged release of the related proopiomelanocortin peptides β- and γ-lipotropins (β- and γ-LPH) and β-endorphin (β-END).
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
Below package inserts are available for further reading:
This drug has been assigned below unique identifiers within the countries it is being marketed: